ISSN: 0923-7534

Annals of Oncology Q1 Unclaimed

Elsevier Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Annals of Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 229. It is an CC BY Journal with a Single blind Peer Review review system The scope of the journal is focused on Cancer, Oncology, Systemic anticancer therapy, Molecular pathology. It has an SJR impact factor of 1,039 and it has a best quartile of Q1. It is published in English.

Annals of Oncology focuses its scope in these topics and keywords: cancer, patients, advanced, phase, lung, metastatic, clinical, treatment, trial, ii, ...

Type: Journal

Type of Copyright: CC BY

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q1) Hematology (Q2) Oncology (Q2)

Price

- €

Gold OA

-

Green OA

- €

Non OA

Metrics

1,039

SJR Impact factor

229

H Index

1047

Total Docs (Last Year)

8249

Total Docs (3 years)

9316

Total Refs

15748

Total Cites (3 years)

7777

Citable Docs (3 years)

1,85

Cites/Doc (2 years)

8,9

Ref/Doc

Other journals with similar parameters

Accounts of Chemical Research Q1
Annual Review of Pathology: Mechanisms of Disease Q1
The Lancet Global Health Q1
Journal of Experimental Medicine Q1
Annual Review of Clinical Psychology Q1

Aims and Scope

Best articles

A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267

A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients

Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials

An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Are liquid biopsies a surrogate for tissue EGFR testing?

Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer

Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial

Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome

SHOW MORE ARTICLES

BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection

BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease

Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial

Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma

Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer

Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?

Coming into focus: the nonovarian origins of ovarian cancer

Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009

Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma

Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer

Crossover is not associated with faster trial accrual

Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'

Comments

No comments ... Be the first to comment!

Publication speed

Review quality

Edition and editorial team

Paper Link

Attach one of your papers. We need to confirm that you have had a relation with this journal in order to review its service.